This free white paper contains our expert insights on creating a credible biomarker strategy for accelerated drug development and approval.
A biomarker is a characteristic that is measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The use of biomarkers is key to understanding drug mechanisms. While biomarkers can play a crucial role in informing drug label claims, this white paper will explain why the inclusion and assessment of biomarkers within drug development can also inform many critical research decisions.
学べる内容
- Incorporate hypothesis testing into trial design: Use biomarkers to validate drug targets and avoid costly clinical trial failures
- Set safety thresholds for clinical trial subjects: Establish “do-not-exceed” limits to mitigate drug safety risks
- Align with regulators regarding your clinical development plan: Select surrogate endpoints that meet FDA guidances
With this knowledge, you’ll be able to:
- Select the most promising drug candidates
- Demonstrate proof of biology and concept
- Optimize drug dosing and select the right patient population for your drug
- Accelerate your path to regulatory approval
- Make data-driven decisions to enhance drug safety and efficacy
Get your free white paper for insights on creating a robust biomarker strategy
Submit the form below to download your white paper and learn the essential components of a drug development program’s biomarker strategy!
